- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.10. | Medicenna Therapeutics Corp.: Medicenna Announces Oral Presentation of Topline Data from the Phase 1/2 ABILITY-1 Study of MDNA11 at SITC 2026 | 2 | GlobeNewswire (USA) | ||
| 02.10. | Medicenna Therapeutics Corp.: Medicenna Announces Results of Annual General and Special Meeting of Shareholders | 171 | GlobeNewswire (Europe) | TORONTO and HOUSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company developing Superkines... ► Artikel lesen | |
| 24.09. | Stocks in Play: Medicenna Therapeutics Corp. | - | Baystreet.ca | ||
| 24.09. | Medicenna Therapeutics Corp.: Medicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting | 1 | GlobeNewswire (USA) | ||
| MEDICENNA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 14.08. | Stocks in Play: Medicenna Therapeutics Corp. | - | Baystreet.ca | ||
| 14.08. | Medicenna Therapeutics Corp. GAAP EPS of -$0.06 | 1 | Seeking Alpha | ||
| 02.07. | Medicenna stock price target maintained at $2.50 by H.C. Wainwright | 2 | Investing.com | ||
| 26.06. | Medicenna Therapeutics Corp. GAAP EPS of -C$0.22 | 1 | Seeking Alpha | ||
| 26.06. | Medicenna Therapeutics Corp.: Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights | 347 | GlobeNewswire (Europe) | MDNA11, as a single agent or in combination with pembrolizumab, continues to demonstrate compelling anti-tumor activity in patients with advanced or metastatic cutaneous melanoma, endometrial cancer... ► Artikel lesen | |
| 11.06. | Medicenna Therapeutics Corp: Medicenna receives two U.S. patents | 1 | Stockwatch | ||
| 03.06. | Medicenna Therapeutics Corp: Medicenna highlights MDNA11 melanoma trial data | 3 | Stockwatch | ||
| 03.06. | Stocks in Play: Medicenna Therapeutics Corp. | 1 | Baystreet.ca | ||
| 29.05. | Medicenna Therapeutics Corp: Medicenna Therapeutics closes $4.44M public offering | 1 | Stockwatch | ||
| 28.05. | Medicenna Therapeutics Corp.: Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs | 1 | GlobeNewswire (USA) | ||
| 22.05. | Medicenna Therapeutics Corp: Medicenna files prospectus for $5-million offering | 1 | Stockwatch | ||
| 22.05. | Medicenna Therapeutics Corp.: Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet | 3 | GlobeNewswire (USA) | ||
| 19.05. | Medicenna Therapeutics Corp: Medicenna sets out terms of public offering | 1 | Stockwatch | ||
| 19.05. | Stocks in Play: Medicenna Therapeutics Corp. | 1 | Baystreet.ca | ||
| 19.05. | Medicenna prices public offering at $0.50 per unit | 5 | Investing.com | ||
| 13.05. | Medicenna launches public offering to fund clinical programs | 2 | Investing.com |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ALAUNOS THERAPEUTICS | 3,940 | +30,03 % | Paragon Labs Adds Former Apogee Leaders As Alaunos Completes Velaris Acquisition; Stock Up | WASHINGTON (dpa-AFX) - Paragon Labs announced that several former senior executives from Apogee Therapeutics (APGE) have joined its leadership team, while Alaunos Therapeutics, Inc. (TCRT) completed... ► Artikel lesen | |
| QIAGEN | 41,095 | +1,47 % | QIAGEN N.V.: QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosis | Global TB Summit brings together international experts as persistent disease burden and funding pressures challenge progress against tuberculosis QuantiFERON-TB Gold Plus detects tuberculosis... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 242,87 | -0,14 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| EVOTEC | 2,640 | +8,02 % | Aufgepasst! Den nächsten Kurstreiber früh erkennen, diese Meilensteine könnten die Bewertung von Lahontan Gold, Evotec und Deutz bald verändern! | Zuschlagen, bevor die Aktie anspringt! Dabei ist entscheidend, den Auslöser für den nächsten Kursimpuls früh genug zu erkennen. Lahontan Gold arbeitet an der Inbetriebnahme einer historischen Goldmine... ► Artikel lesen | |
| BIONTECH | 80,00 | +0,76 % | BERENBERG stuft Biontech auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat Biontech auf "Buy" mit einem Kursziel von 140 US-Dollar belassen. Auf dem jährlichen Esmo-Krebskongress ab dem 23. Oktober in Madrid erwarte... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 15,320 | -1,29 % | AstraZeneca and Daiichi Sankyo to collaborate with Summit Therapeutics | ||
| RECURSION PHARMACEUTICALS | 3,795 | -1,04 % | 90% der Wirkstoffkandidaten scheitern: Wie Nvidia, Bristol Myers Squibb, Recursion und NeuroThera das größte Pharmaproblem angreifen | ||
| MBX BIOSCIENCES | 49,250 | +0,51 % | Stifel raises MBX Biosciences price target to $84 on obesity drug data | ||
| NURIX THERAPEUTICS | 22,940 | +3,66 % | Nurix Therapeutics Swings To Profit In Q3 On Roche Licensing Revenue | SOUTH SAN FRANCISCO (dpa-AFX) - Nurix Therapeutics, Inc. (NRIX), clinical-stage biopharmaceutical company, reported a swing to profit in the third quarter from a loss in the year-ago period... ► Artikel lesen | |
| CG ONCOLOGY | 62,96 | +0,97 % | CG Oncology appoints Isabel Kalofonos as chief commercial officer | ||
| MODERNA | 194,50 | +1,53 % | Nach 200 %-Rally Moderna Aktie jetzt verkaufen? Comeback bei Standard Lithium und HPQ Silicon? | Die Aktie von Moderna hat fulminante Wochen hinter sich. Seit Mitte August ist die Aktie des Biotechunternehmens von 63 USD auf über 200 USD geschossen. Doch jetzt gießen Analysten Wasser ins Kursfeuerwerk.... ► Artikel lesen | |
| TREVI THERAPEUTICS | 12,310 | +0,16 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual Meeting | ||
| TANGO THERAPEUTICS | 22,430 | +0,90 % | JPMorgan reiterates Tango Therapeutics stock rating ahead of ESMO data | ||
| ERASCA | 14,710 | -0,54 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen |
Das Unternehmen MEDICENNA THERAPEUTICS CORP kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDICENNA THERAPEUTICS CORP finden Sie auf Wallstreet Online.